Allergan to establish R&D presence in Cambridge, Massachusetts

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

"One of the driving sources of innovation today comes from smaller biotechnology and pharma companies. Our new, strategic presence in Kendall Square will allow us to more easily interact and engage with venture firms and start ups in the area," said David Nicholson, EVP & Chief R&D Officer. "I am confident that our new location in Cambridge, along with Don's deep expertise will accelerate the evaluation of scientific opportunities and further deliver on our Open Science model and the next wave of potentially transformational medicines."

Dr Frail joined Allergan in 2014, relocating from Boston to the Allergan R&D center in Irvine, CA, and has led the Research, Clinical Pharmacology, Toxicology and ADME departments including the External Science & Innovation initiatives to evaluate and implement partnerships and acquisitions across Allergan's four key therapeutic areas. Don will continue to lead the Irvine team as well. Previously, Frail led the Emerging Innovations Unit at AstraZeneca, the Indications Discovery Units at Pfizer and the CNS Discovery organization at Pharmacia.

"I'm looking forward to returning to the Boston area to establish Allergan's new presence where we will continue to identify cutting-edge technologies and opportunities that deliver the highest value to patients and their healthcare providers. Our Irvine site will continue to be the home of R&D and retain its long-established External Scientific Innovation and Non-Clinical Translational Sciences team. The new Cambridge group will be fully integrated with the Allergan organization, and serve as a portal to our other R&D sites in Madison NJ, San Francisco area, and globally," said Don Frail.